Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro.
Mycoplasmas may be associated with rheumatoid arthritis in various animal hosts. In humans, mycoplasma arthritis has been recorded in association with hypogammaglobulinemia. Mycoplasma fermentans is one mycoplasma species considered to be involved in causing arthritis. To clarify which mycoplasmal compounds contribute to the inflammatory, bone-destructive processes in arthritis, we used a well-defined lipopeptide, 2-kDa macrophage-activating lipopeptide (MALP-2) from M. fermentans, as an example of a class of macrophage-activating compounds ubiquitous in mycoplasmas, to study its effects on bone resorption. MALP-2 stimulated osteoclast-mediated bone resorption in murine calvaria cultures, with a maximal effect at around 2 nM. Anti-inflammatory drugs inhibited MALP-2-mediated bone resorption by about 30%. This finding suggests that MALP-2 stimulates bone resorption partially by stimulating the formation of prostaglandins. Since interleukin-6 (IL-6) stimulates bone resorption, we investigated IL-6 production in cultured calvaria. MALP-2 stimulated the liberation of IL-6, while no tumor necrosis factor was detectable. Additionally, MALP-2 stimulated low levels of NO in calvaria cultures, an effect which was strongly increased in the presence of gamma interferon, causing an inhibition of bone resorption. MALP-2 stimulated the bone-resorbing activity of osteoclasts isolated from long bones of newborn rats and cultured on dentine slices without affecting their number. In bone marrow cultures, MALP-2 inhibited the formation of osteoclasts. It appears that MALP-2 has two opposing effects: it increases the bone resorption in bone tissue by stimulation of mature osteoclasts but inhibits the formation of new ones.
Piec
G
G
Department of Clinical Research, Bone Biology, University of Bern, CH-3010 Bern, Switzerland.
Mirkovitch
J
J
Palacio
S
S
Mühlradt
P F
PF
Felix
R
R
D000818:Animals; D001854:Bone Marrow Cells; D001862:Bone Resorption; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D046508:Culture Techniques; D015850:Interleukin-6 / Q000096:biosynthesis; D055666:Lipopeptides; D051379:Mice; D016858:Mycoplasma fermentans / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology*; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D051381:Rats; D012886:Skull
D015850:Interleukin-6; D055666:Lipopeptides; D009842:Oligopeptides; D011448:Prostaglandin Antagonists; D009569:Nitric Oxide; C106335:macrophage stimulatory lipopeptide 2; D002118:Calcium